Key Highlights

  • Stevanato Group (NYSE:STVN) dropped roughly 24% to 26% in the November 3, 2026 session, with one morning snapshot at USD 14.63 against a USD 19.74 close on November 2.
  • Third-quarter Revenue of EUR 326.1 million topped about EUR 320.9 million expected and rose 8%, while adjusted EPS of EUR 0.16 matched analyst estimates.
  • Management guided only low single-digit revenue growth for 2027 and left 2026 revenue guidance at EUR 1.26 billion to EUR 1.28 billion.
  • GLP-1 products accounted for about 17% to 18% of third-quarter revenue, while Demand from other biologic drugs rose more than 30%, according to published coverage.

What Stevanato Reported

Stevanato Group (NYSE:STVN) makes glass vials, syringes and drug-delivery devices for drugmakers. Its third-quarter report on November 3, 2026 showed revenue of EUR 326.1 million, ahead of the roughly EUR 320.9 million analysts had pencilled in, and adjusted EPS of EUR 0.16, in line with forecasts. The headline numbers were not the issue. Investors focused on the outlook, because the company expects only low single-digit revenue growth in 2027 while keeping its 2026 revenue range intact. The 2026 range of EUR 1.26 billion to EUR 1.28 billion is therefore not in question, and the debate is about growth beyond that base year.

Order Intake and the GLP-1 Mix

Published coverage says new orders improved during the quarter but finished below the company's signed-order targets, and orders lead sales. GLP-1 customers made up about 17% to 18% of third-quarter revenue. Management said weaker GLP-1 revenue was offset by other biologic drugs, which grew more than 30%. For a supplier, order timing matters more than any single quarter, because vial and syringe capacity is committed ahead of customer launches. Stevanato (NYSE:STVN) must now show that orders turn into 2027 sales faster than the guidance implies. Put simply, a supplier like this gets paid when customers Fill and ship their drugs, so a slower order book usually appears as weaker sales a few quarters later. Orders did improve sequentially, which points the right way even though the level fell short.

Size of the Move and the Risks

Sources disagree on the size of the drop. One snapshot showed a fall of about 25.9% in morning trade, on Volume near four times the three-month average and a Market Value close to USD 4 billion, while another report put it at about 24%. Treat the figure as a range. The USD 14.63 level was an intraday price, not a close. Risks include customer concentration in obesity drugs, pricing pressure on injectable devices, capacity costs and slower biologic launches. Readers should weigh the 2027 commentary alongside any fresh order data in coming quarters, rather than assume either a rebound or a further fall. A decline this size can also reflect positioning, since a stock that has rallied into results has more room to disappoint. Prices in the first sessions after a guidance reset often swing several points as analysts revise their models.

Where Things Stand

Stevanato Group (NYSE:STVN) fell close to 25% because a revenue beat was outweighed by a low single-digit growth view for 2027 and orders that ended the quarter below target. GLP-1 exposure of about 17% to 18% is material but not dominant, and other Biologics are growing faster. The next catalysts are fourth-quarter results, any order updates and whether the 2026 revenue range of EUR 1.26 billion to EUR 1.28 billion holds.